KRKA (KRK): End of litigation relating to esomeprazole product in Denmark - raport 15
Raport ESPI
UNI - EN REPORT No
15
/
2019
UNI - EN REPORT No15/2019
Krka, d. d., Novo mesto (hereinafter referred to as Krka) informs the interested public that its subsidiary Krka Sverige AB, Sweden received the decision of the Danish Supreme Court where the court rejected the application for leave to appeal by AstraZeneca against the decision of the Eastern High Court in Copenhagen.
The dispute relating to esomperazole in Denmark has therefore ended.
Krka published notices about the litigation in Denmark on 15 December 2010, 11 April 2013, 25 February 2016 and 19 October 2018.
